{"id":"axitinib-plus-toripalimab","_chembl":null,"_fixedAt":"2026-03-30T11:30:25.487753","allNames":"axitinib plus toripalimab","_dailymed":null,"mechanism":{"target":"VEGFR, PD-1","drugClass":"VEGFR inhibitor, PD-1 inhibitor","explanation":"Axitinib blocks VEGF receptors to prevent blood vessel growth in tumors, while Toripalimab binds to PD-1 to activate T-cells, improving the body's ability to fight cancer.","oneSentence":"Axitinib plus Toripalimab targets VEGF receptors and PD-1, inhibiting angiogenesis and enhancing immune response against cancer cells."},"_scrapedAt":"2026-03-28T00:43:54.166Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"revenueYear":2025,"annualRevenue":923,"revenueSource":"SEC 8-K Pfizer (2026-02-03)","revenueCurrency":"USD","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:46:19.066292","revenueExtractedBy":"revenue-sec"},"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:37:19.138954+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT05738694","phase":"PHASE3","title":"Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma","status":"RECRUITING","sponsor":"ZHOU FANGJIAN","startDate":"2023-04-19","conditions":"Renal Cell Carcinoma, Neoadjuvant","enrollment":298},{"nctId":"NCT04394975","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-08-20","conditions":"Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1","enrollment":421},{"nctId":"NCT04640545","phase":"PHASE1","title":"A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma","status":"COMPLETED","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2020-05-12","conditions":"Advanced Melanoma","enrollment":79},{"nctId":"NCT07172386","phase":"PHASE2","title":"Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2025-07-31","conditions":"Renal Cell Carcinoma (RCC)","enrollment":40},{"nctId":"NCT06889649","phase":"PHASE2","title":"SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2019-01-01","conditions":"Radiation Therapy, Targeted Therapy, Immunotherapy","enrollment":30},{"nctId":"NCT06211114","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-02-09","conditions":"Collecting Duct Carcinoma","enrollment":30},{"nctId":"NCT06690697","phase":"PHASE2","title":"Combination of Toripalimab and JS004 Therapy for ccRCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-06-01","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":80},{"nctId":"NCT06279403","phase":"PHASE2","title":"Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-03-01","conditions":"Clear-cell Metastatic Renal Cell Carcinoma, Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy","enrollment":20},{"nctId":"NCT04118855","phase":"PHASE2","title":"Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2020-03-01","conditions":"Neoadjuvant Therapy of Non-metastatic Locally Advanced Renal Cell Carcinoma","enrollment":20},{"nctId":"NCT04010071","phase":"PHASE2","title":"Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-05-01","conditions":"Hepatobiliary Neoplasm, Liver Neoplasm, Biliary Tract Neoplasms","enrollment":60},{"nctId":"NCT05768464","phase":"PHASE2","title":"Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-02-01","conditions":"Non-clear Renal Cell Carcinoma","enrollment":30},{"nctId":"NCT04180995","phase":"PHASE2","title":"Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2019-08-06","conditions":"Mucosal Melanoma","enrollment":30},{"nctId":"NCT03086174","phase":"PHASE1","title":"Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2017-03-31","conditions":"Kidney Cancer Stage Iv, Advanced Melanoma","enrollment":24},{"nctId":"NCT04459663","phase":"PHASE2","title":"JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.","status":"UNKNOWN","sponsor":"Li Zhang, MD","startDate":"2020-08-31","conditions":"Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT04385654","phase":"PHASE2","title":"Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2020-06","conditions":"Neoadjuvant Therapy, Advanced Cancer, Metastatic Kidney Cancer","enrollment":40},{"nctId":"NCT03941795","phase":"PHASE2","title":"Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2019-11-11","conditions":"Advanced Mucosal Melanoma","enrollment":99}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"_revenueScrapedAt":"2026-04-01 10:46:19.090454+00","rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Axitinib plus Toripalimab","genericName":"axitinib-plus-toripalimab","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Monoclonal antibody","firstApprovalDate":"","aiSummary":"Axitinib plus Toripalimab is being studied in clinical trials for various conditions, including kidney cancer and melanoma. Toripalimab is a programmed cell death protein 1 (PD-1) antagonist, a type of antibody that works by blocking the PD-1 protein.","enrichmentLevel":5,"visitCount":8,"trialStats":{"total":4,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:37:19.138954+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}